Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
NCT00606879
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
46
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Cancer
Interventions
DRUG:
SGX523 Capsules
Sponsor
SGX Pharmaceuticals, Inc.